Rebamipide

Rebamipide is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. Additionally, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense. Its therapeutic use is listed as gastrointestinal agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Proamipide, Mucosta, Rebator and Pramipide. Its PubChem CID is 5042.

CAS No 90098-04-7
Molecular Formula C19H15ClN2O4
Molecular Weight 370.8 g/mol
Synonyms 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid

Frequently Asked Questions